Skip to content

Virtual Patent Marking

The following Outset Medical products are protected by patents in the United States and elsewhere. This web page is provided to satisfy the virtual patent marking provisions of various jurisdictions including the virtual patent marking provisions of Section 16 of the America Invents Act. It is also intended to serve as notice under 35 U.S.C. § 287(a).

Other products not listed here may be protected by one or more patents in the United States and elsewhere.

Additional patents are pending in the United States and elsewhere.

Patents

US20200061273A1
US20210244869A1
US20210252204A1
US20220040389A1
US8753515B2
US20110132838A1
US20160339162A1
US9545469B2
US20150343135A1
US9579440B2
US20150343131A1
US20150343132A1
US9504777B2
US9402945B2
US8524086B2
US20150343133A1
US11305040B2
EP3137128A1
EP3193963A1
ES2640953T3
EP3137128A4
EP3193963A4
HK1241772A
EP3193963B1
ES2749975T3
HK1241772A1
AU2019325668A1
EP3137128B1
CA3109237A1
DE602015034970T2
BR112021003168A2
EP3838308A1
EP3840798A1
ES2864727T3
JP2021533881A
HK40050892A
DE602015066049T2
JPWO2020041753A5
EP3840798A4
JP2021533881A5
JP2023025224A
AU2021320862A1
CA3188421A1
BR112023002152A2
EP4192541A1
WO2023137392A1
JP2023538525A
JP2017514653A
JP2017528252A
JP6637035B2
JP6657186B2
JP2017514653A5
JP2020096876A
JP7191880B2
CN105288762A

Updated: January 9, 2024

INDICATIONS FOR USE:

The Tablo® Hemodialysis System and TabloCart™ is indicated for use in patients with acute and/or chronic renal failure, with or without ultrafiltration, in an acute or chronic care facility. Treatments must be administered under physician’s prescription and observed by a trained individual who is considered competent in the use of the device. The Tablo Hemodialysis System is also indicated for use in the home. Treatment types available include Intermittent Hemodialysis (IHD), Sustained Low Efficiency Dialysis (SLED/ SLEDD), Prolonged Intermittent Renal Replacement Therapy (PIRRT), and Isolated Ultrafiltration.

This device is not indicated for continuous renal replacement therapy (CRRT) and is cleared for use for up to 24 hours. The dialysate generated by this device is not sterile and should not be used for intravenous (IV) infusion.
2214-v2
Stay connected
© 2024 Outset Medical, Inc. All rights reserved. Outset, Tablo, TabloCart, MyTablo, TabloHub, and Better Begins Now are trademarks of our company.